| Tbio | AF4/FMR2 family member 4 |
Key component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. In the SEC complex, AFF4 acts as a central scaffold that recruits other factors through direct interactions with ELL proteins (ELL, ELL2 or ELL3) and the P-TEFb complex. In case of infection by HIV-1 virus, the SEC complex is recruited by the viral Tat protein to stimulate viral gene expression.
The protein encoded by this gene belongs to the AF4 family of transcription factors involved in leukemia. It is a component of the positive transcription elongation factor b (P-TEFb) complex. A chromosomal translocation involving this gene and MLL gene on chromosome 11 is found in infant acute lymphoblastic leukemia with ins(5;11)(q31;q31q23). [provided by RefSeq, Oct 2011]
The protein encoded by this gene belongs to the AF4 family of transcription factors involved in leukemia. It is a component of the positive transcription elongation factor b (P-TEFb) complex. A chromosomal translocation involving this gene and MLL gene on chromosome 11 is found in infant acute lymphoblastic leukemia with ins(5;11)(q31;q31q23). [provided by RefSeq, Oct 2011]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| non-small cell lung cancer | 2890 | 7.0e-11 |
| juvenile dermatomyositis | 1187 | 1.5e-06 |
| acute quadriplegic myopathy | 1158 | 2.1e-06 |
| malignant mesothelioma | 3232 | 9.6e-06 |
| atypical teratoid / rhabdoid tumor | 5112 | 4.1e-05 |
| medulloblastoma, large-cell | 6241 | 4.5e-05 |
| ovarian cancer | 8520 | 7.3e-05 |
| glioblastoma | 5792 | 1.7e-04 |
| group 4 medulloblastoma | 1855 | 7.4e-04 |
| osteosarcoma | 7950 | 9.5e-04 |
| intraductal papillary-mucinous adenoma (IPMA) | 2955 | 1.9e-03 |
| intraductal papillary-mucinous carcinoma (IPMC) | 2989 | 2.3e-03 |
| ependymoma | 4679 | 4.2e-03 |
| pediatric high grade glioma | 1064 | 8.3e-03 |
| lung cancer | 4740 | 1.1e-02 |
| pancreatic cancer | 2398 | 1.5e-02 |
| aldosterone-producing adenoma | 665 | 1.8e-02 |
| primary pancreatic ductal adenocarcinoma | 1109 | 1.9e-02 |
| oligodendroglioma | 2850 | 3.3e-02 |
| astrocytic glioma | 2597 | 3.7e-02 |
| Breast cancer | 3578 | 3.8e-02 |
| Disease | log2 FC | p |
|---|---|---|
| acute quadriplegic myopathy | 1.468 | 2.1e-06 |
| aldosterone-producing adenoma | -1.203 | 1.8e-02 |
| astrocytic glioma | 1.500 | 3.7e-02 |
| atypical teratoid / rhabdoid tumor | 1.300 | 4.1e-05 |
| Breast cancer | 1.800 | 3.8e-02 |
| ependymoma | 1.500 | 4.2e-03 |
| glioblastoma | 1.200 | 1.7e-04 |
| group 4 medulloblastoma | 1.300 | 7.4e-04 |
| intraductal papillary-mucinous adenoma (... | 2.100 | 1.9e-03 |
| intraductal papillary-mucinous carcinoma... | 1.500 | 2.3e-03 |
| juvenile dermatomyositis | 1.019 | 1.5e-06 |
| lung cancer | -1.900 | 1.1e-02 |
| malignant mesothelioma | -1.200 | 9.6e-06 |
| medulloblastoma, large-cell | 1.400 | 4.5e-05 |
| non-small cell lung cancer | -1.196 | 7.0e-11 |
| oligodendroglioma | 1.500 | 3.3e-02 |
| osteosarcoma | 1.410 | 9.5e-04 |
| ovarian cancer | -1.400 | 7.3e-05 |
| pancreatic cancer | 1.300 | 1.5e-02 |
| pediatric high grade glioma | 1.100 | 8.3e-03 |
| primary pancreatic ductal adenocarcinoma | 1.327 | 1.9e-02 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG | ||
| Inparanoid EggNOG | ||
| OMA EggNOG | ||
| Inparanoid OMA |
MNREDRNVLRMKERERRNQEIQQGEDAFPPSSPLFAEPYKVTSKEDKLSSRIQSMLGNYDEMKDFIGDRS 1 - 70 IPKLVAIPKPTVPPSADEKSNPNFFEQRHGGSHQSSKWTPVGPAPSTSQSQKRSSGLQSGHSSQRTSAGS 71 - 140 SSGTNSSGQRHDRESYNNSGSSSRKKGQHGSEHSKSRSSSPGKPQAVSSLNSSHSRSHGNDHHSKEHQRS 141 - 210 KSPRDPDANWDSPSRVPFSSGQHSTQSFPPSLMSKSNSMLQKPTAYVRPMDGQESMEPKLSSEHYSSQSH 211 - 280 GNSMTELKPSSKAHLTKLKIPSQPLDASASGDVSCVDEILKEMTHSWPPPLTAIHTPCKTEPSKFPFPTK 281 - 350 ESQQSNFGTGEQKRYNPSKTSNGHQSKSMLKDDLKLSSSEDSDGEQDCDKTMPRSTPGSNSEPSHHNSEG 351 - 420 ADNSRDDSSSHSGSESSSGSDSESESSSSDSEANEPSQSASPEPEPPPTNKWQLDNWLNKVNPHKVSPAS 421 - 490 SVDSNIPSSQGYKKEGREQGTGNSYTDTSGPKETSSATPGRDSKTIQKGSESGRGRQKSPAQSDSTTQRR 491 - 560 TVGKKQPKKAEKAAAEEPRGGLKIESETPVDLASSMPSSRHKAATKGSRKPNIKKESKSSPRPTAEKKKY 561 - 630 KSTSKSSQKSREIIETDTSSSDSDESESLPPSSQTPKYPESNRTPVKPSSVEEEDSFFRQRMFSPMEEKE 631 - 700 LLSPLSEPDDRYPLIVKIDLNLLTRIPGKPYKETEPPKGEKKNVPEKHTREAQKQASEKVSNKGKRKHKN 701 - 770 EDDNRASESKKPKTEDKNSAGHKPSSNRESSKQSAAKEKDLLPSPAGPVPSKDPKTEHGSRKRTISQSSS 771 - 840 LKSSSNSNKETSGSSKNSSSTSKQKKTEGKTSSSSKEVKEKAPSSSSNCPPSAPTLDSSKPRRTKLVFDD 841 - 910 RNYSADHYLQEAKKLKHNADALSDRFEKAVYYLDAVVSFIECGNALEKNAQESKSPFPMYSETVDLIKYT 911 - 980 MKLKNYLAPDATAADKRLTVLCLRCESLLYLRLFKLKKENALKYSKTLTEHLKNSYNNSQAPSPGLGSKA 981 - 1050 VGMPSPVSPKLSPGNSGNYSSGASSASASGSSVTIPQKIHQMAASYVQVTSNFLYATEIWDQAEQLSKEQ 1051 - 1120 KEFFAELDKVMGPLIFNASIMTDLVRYTRQGLHWLRQDAKLIS 1121 - 1163 //
